{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000095","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-10-29T20:12:11+00:00","discovered_at":"2026-10-29T20:13:00.111726+00:00","generated_at":"2026-10-29T20:13:07.337619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immuneering Q3 2026 net loss $24.2M; MAPKeeper 301 enrollment ahead of schedule, runway to 4Q 2028","bullets":["Net loss attributable to common stockholders $24.2M, or $0.37/share, vs $15.0M ($0.38/share) in Q3 2025; R&D $20.7M vs $10.9M on higher clinical and personnel costs.","Cash, cash equivalents and marketable securities $166.1M at Sept 30, 2026, down from $217.0M at Dec 31, 2025; runway now funded into 4Q 2028.","Phase 2 1L pancreatic cancer atebimetinib + mGnP arm (N=55) follow-up extended because patients are living longer than projected; topline update now 1H 2027.","Phase 3 MAPKeeper 301 enrollment ahead of schedule; target expanded from 510 to ~570 patients, with potential to accelerate current mid-2028 topline guidance.","CEO Zeskind cited 17.3 months median overall survival reported at ASCO; first lung cancer patient in atebimetinib + cemiplimab Phase 2 dosed in 4Q 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000095","json":"https://secwatch.observer/filing/0001790340-26-000095.json","markdown":"https://secwatch.observer/filing/0001790340-26-000095.md","text":"https://secwatch.observer/filing/0001790340-26-000095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/0001790340-26-000095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-29T20:13:07.337619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}